Cynapsus: Analysts Expect Cynapsus Therapeutics Inc. (NASDAQ:CYNA) to Announce ($0.75) EPS
Shares of Cynapsus Therapeutics Inc. (NASDAQ:CYNA) have been given a consensus broker rating score of 1.50 (Buy) from the four brokers that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a hold rating and three have given a strong buy rating to the company. Cynapsus Therapeutics' rating [...]
Read full article »
Cynapsus is a central nervous system pharmaceutical company that develops sublingual film product to treat the motor symptoms of Parkinson's disease.
Read more